USD 329.00

Basic information on Amrubicin.

Contraindications and precautions: strictly follow the dosage. In case of complications, discontinue the drug treatment.

Amrubicin is a third-generation lung cancer drug. The drug is distributed in Japan since 2005 by Nippon Kayaku.

Pharmacodynamics of Amrubicin.

The anthracycline glycoside group of antibiotics, including amrubicin, is a group of potent anti-cancer agents with strong activity against both solid tumors and hematological malignancies. Amrubicin is a derivative of 9-aminoanthracycline and contributes to the inhibition of cell growth by stabilizing protein-DNA complexes, followed by double-stranded DNA breaks, which are mediated by the enzyme topoisomerase II

The mechanism of action of Amrubicin.

As anthracycline, amrubicin has antimitotic and cytotoxic activity through various mechanisms of action. Amrubicin has been found to form complexes with DNA by intercalation between base pairs and inhibits the activity of the enzyme topoisomerase II by stabilizing the DNA-topoisomerase II complex, which prevents the ligation-re-polymerization reaction, which usually catalyzes the topoisomerase II

Toxicity of Amrubicin

Based on acute toxicity studies of intravenous doses, the lethal dose of up to 50% of animals was estimated at 42 mg / kg in mice, 14 mg / kg in rats and 4 mg / kg for dogs